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3Framework for presentation
4Theranostics
Therapy with Diagnostics
Term coined by  John Funkhouser,CEO 
of PharmaNetics term to describes his 
companies model of philosophy of 
diagnosis  and therapy techniques
 Theranostics is therapy based on an 
evidence derived diagnosis leading to 
personalized medicine for each 
patient.
 Theranostics is the future of precise 
medicinePicture from http://theranostics.com.au/what-is-theranostics/
Theranostics In Nuclear Medicine
• Iodine-131 for Diagnosis and Therapy Samuel M. Seidlin in1946
• Diagnosis with low dose of 131I followed by therapeutic intervention with large doses for the 
management of thyroid cancer.
• Some other terminology also used  for Theranostics:
Theranostics
Targeted radionuclide therapy 
Molecular Imaging 
Molecular therapy
Personalized medicine
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Iodine-131 for Diagnosis and Therapy Samuel M. Seidlin in1946
Pic from Life magazine oct,1949 edition
PubMed-derived number of publications including the term theranostic or theragnostic during each year from 
2001 to 2017 (search performed July 16, 2017). Ken Herrmann et al. J Nucl Med 2017;58:1S-2S
Theranostics In Nuclear Medicine
7• Radioisotopes
• SPECT or PET radionuclide 
for diagnosis
• alpha, beta or Auger 
electron emitting 
radionuclides for therapy 
• A carrier molecule that will 
target the disease
• Antigen
• Peptide
• Enzyme inhibitor
• Other small molecules
Diagnostic Therapeutic
Iodine-131 Iodine-131
Iodine-123
Iodine-124
Iodine-131
Indium-111 Yttrium-90
Yttrium-86 Yttrium-90
Gallium-68
Yttrium-90
Lutetium-177
Iodine-131
Theranostics In Nuclear Medicine
Variety of mechanisms exist for targeting the radionuclide to the disease 
Targeting Mechanisms
Antigen binding
Receptor Mapping
Enzyme Activity
DNA Synthesis
Amino acid transport
Accumulation via a shuttle
Accumulation via blocked metabolism
Theranostics In Nuclear Medicine
9Theranostics In Nuclear Medicine
Lu-177:Quick  General facts
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Discovered in 1907
Discovered by Georges Urbain in Paris, France and independently by Charles 
James in New Hampshire, USA
Origin of the name The name derives from the Romans' name for Paris, 'Lutetia'.
Group in Periodic Table Lanthanides
Atomic Number 71
Atomic Mass 174.967 amu
Biological use No known biological role. It has low toxicity
Oxidation states +3
Key Isotopes Lu-175,Lu-176,Lu-176m,Lu-177
Lu-177: Important Radiological facts
Physical Data
Radiation Betas
Gamma
497 keV (78%), 384 keV (9.1 %), 176 keV (12.2 %)
113 keV (6.6%),210 keV (11%)
Gamma Constant 0.1 mR/hr per 1 mCi at 30 cm
Half life Physical
Biological
Effective
6.73 days
GI: ~1 day; Lungs: ~30 days
GI: ~0.9 days; Lungs: ~6 days
Specific Activity 1.1E5 Ci/g [4.1E15 Bq/g] max
Intake Routes Ingestion, inhalation, puncture, wound, skin 
contamination (absorption)
Shielding HVL (For Betas)
HVL  for Lead
TVL  for Lead
0.135 cm Plexiglas
0.6 mm (0.02 inches)
2.1 mm (0.08 inches)
Special precaution Avoid skin contamination [absorption], 
ingestion, inhalation, & injection [all routes 
of intake]
mean penetration range of β− particles 670 µm
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Source :http://www.hpschapters.org/northcarolina/NSDS/177LuPDF.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463871/pdf/13139_2014_Article_315.pdf
Lu-177 Production Methods
• Mostly Produce in Nuclear Reactor.
• Lutetium-177 is produced in a nuclear reactor 
through ‘direct’ method by the neutron activation of 
enriched Lu-176 target, also called as CA(Carrier 
aided).
• ‘indirect’ method of neutron activation of enriched 
Yb-176 target followed by beta decay of Yb-177 to 
Lu-177, also known as NCA (No carrier Aided).
• Few studies reported cyclotron production, but not 
appropriate for large production.
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Picture source : https://www.rcm.tum.de/index.php?id=54&L=1
Lu-177 Production Methods
•
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NCA (No carrier aided) Lu-177 CA (Carrier aided) Lu-177
Lu-176(n,γ) Lu-177 Yb-176(n,γ)Yb-177 ->Lu-177
The specific activity of Lu-177 can be achieved up to 70 
Ci (2590 GBq)/mg, which is less than theoretical required 
specific activity.
The specific activity will be closer to or equivalent to the 
theoretical specific activity of 111.11 Ci (4111 Gbq)/mg of 
Lu-177
Also produce a co-product of Lu-177m which is very long 
lived radionuclide impurity (carrier impurity)
No Lu-177m production which keeps the specific activity 
at highest
Easily producible in any nuclear reactor as required 
neutron flux is easily available in all reactors
Requirement of high flux nuclear reactor 
It is highly essential that very efficient chemical separation 
methods are available for separation of the microscopic levels of 
Lu-177 from the macroscopic mass of Yb, otherwise Yb 
contamination will adversely affect the complexation chemistry of 
Lu+3.
• The mean penetration range of β− particles emitted by Lu-177 in soft tissue is 670 μm, making this
radionuclide ideal for delivering energy to small volumes, including micro metastatic disease, and
tumour cells near the surface of cavities.
• Lu-177 is found to be effective in localizing cytotoxic radiation in relatively small areas and
proficient in destroying small tumours as well as metastatic lesions with less damage to
surrounding normal tissue due to the maximal tissue penetration of 2 mm.
• Lu-177 emits low-energy γ-rays (gamma radiation) which allow scintigraphy and subsequent
dosimetry with the same therapeutic compound, making Lu-177 a theranostically-desirable
radioisotope.
• Lu-177 have +3 oxidation states which makes its chemistry easy for chemical reactions to form
bonding.
• Lu-177 also have a long half-life (6.73 days) which makes easily transportable radionuclide.
S.No Name of
Radiopharmaceuticals
Used for Clinical trial conducted by and    
approval stage
1. Lu-177-DOTATATE/TOT/NOC Treatment of  GIP-
Neuroendocrine Tumour
Advance Accelerator 
Applications S.A. /FDA 
APPROVED
2. Lu-177-EDTMP Bone metastasis secondary to 
prostate and breast cancer 
IAEA, India, China, 
Uruguay 
Phase II completed
3. Lu-177-PSMA-617/I&T/J591 Labelled PSMA to treat  
metastatic prostate cancer
Endocyte,USA /Phase II 
completed 
4. Lu-177-Rituximab Treatment of non-Hodgkin
lymphoma
Switzerland/Phase II 
completed
5. Lu-177-CC49 Ovarian cancer USA/Phase II
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Lu-177 labelled Radiopharmaceuticals
• A diverse group of tumour originated from 
Neuroendocrine cells.
• Neuroendocrine tumours are the slowest growing 
tumour and misdiagnosed in its early stage and 
due to this late diagnosis patient quality of life get 
affected.
• From 1973 to 2004, incidence of NETs has grown 
by almost 500% (from 1,09/100,000 to 
5,25/100,000 respectively)  in USA.
• In NZ between 2008 to 2012 incidence of NET is 
increased from 7.6% per 100,000 to 8.6% per 
100,000(Kate Parker et al. 2017).
Neuroendocrine tumours (NETs)
Image source:https://www.mja.com.au/journal/2010/193/1/gastrointestinal-neuroendocrine-carcinoid-tumours-current-diagnosis-and  
Pic from different internet sources
Neuroendocrine tumours (NETs)
Neuroendocrine tumours (NETs)
• Characterized by over expression of somatostatin receptors (sst1-5)
• Peptide analogues such as TOC, TATE, NOC having varying affinity to the 
different subtypes of somatostatin receptors can be used for targeting
19

Treatment Method
Neuroendocrine tumours (NETs)
• Lu-177-DOTATATE
• Administered activity:
5.5–7.4 GBq
• Number of cycles: 
three to five
• Time interval between cycles: 
6–12 weeks
https://openi.nlm.nih.gov/detailedresult.php?img=PMC3539351_JAA2012-967347.002&req=4
Treatment Method
Inject 10 mcg/kg I/V  
30 min before or 2 
mg Granisetron 
oral 1hr before 
therapy
Place two 
venflon(one in each 
ACF
Start amino acid I/V 
infusion from one 
venflon @ the rate 
of 300 ml/hour, for 
two 2 liters over 6-7 
hours
After 1 hour of 
starting above 
infusion, start Lu-
177-DOTATATE I/V 
infusion(5.5 -7.4 
GBq) from venflon 
in the other arm 
over 30 min
Discharge patient 
after 24 hrs. from 
ward and send to 
Nuclear Medicine 
for WB and 
SPECT/CT scan
Neuroendocrine tumours (NETs)
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68Ga-DOTATATE 
pretherapy scan
68Ga-DOTATATE 
Post therapy scan 
after two cycles of 
therapy
177Lu-DOTATATE 
Therapy Cycle - I
177Lu-DOTATATE 
Therapy Cycle - II
Picture from: P.D.Hinduja Hospital,Mumbai,India



(J Kwekkeboom et al.,2010)

Lu-177-EDTMP
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Lu-EDTMP is an agent that concentrates in areas of enhanced osteoblastic 
activity due to primary tumours i.e. Breast, prostate
Prostate Cancer 
Targeting Enzyme Activity for 
Theranostics.
One in 7 men are likely to develop 
prostate cancer in life, the probability 
increases as the age advances.  
Serum PSA, Biopsy, CT, MRI and a 
99mTc-MDP scan are used to stage 
prostate cancer.
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Metastatic  castrate resistant Prostate Cancer Management
Wait and watch
Surgery (very rare)
Hormone therapy
Chemotherapy
Radiotherapy
Palliative therapy
Targeted Radionuclide therapy
PSMA is transmembrane enzyme over expressed in prostate adenocarcinoma and 
several other solid tumors.
Each year in New Zealand approximately 3000 men are diagnosed with prostate cancer and 
approximately 600 men die from the disease; 80% of diagnoses are for men aged 60 years 
or more (MOH,2017).
Liver metastases
Left adrenal metastasis
Penile metastasis
Abdominal LN metastasis
Mediastinal LN metastasis
Lung metastasis
Bone metastasis
68Ga-PSMA PET/CT
Prostate Cancer 
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Teaser for the Future
• Pilot Study of Lutetium 177 – PSMA for progressing metastatic 
castrate resistant prostate cancer
• First four patient enrolled
• Started Friday 24 August 2018 
Results from Lu177 Therapy
SNMMI IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostic in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options. 68Ga-
PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease 
with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price 
Jackson, Mark Scalzo, Scott Williams and RodneyHicks Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.
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Will see you all  next year!!!
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